DiagnosticResearch Phase

Gadopentetate Peptide Conjugates

Overview

Gadopentetate peptide conjugates consist of the gadolinium-based contrast agent gadopentetate dimeglumine chemically linked to targeting peptides designed to bind specific tissue markers or receptors. These hybrid molecules combine the MRI contrast properties of chelated gadolinium with the molecular specificity of peptides to enable targeted imaging of tumors, inflammatory lesions, or vascular pathology. Various peptide motifs including RGD sequences and somatostatin analogs have been conjugated to gadolinium chelates for preclinical evaluation.

Key Research Findings

Preclinical studies in rodent tumor models have demonstrated enhanced MRI contrast at target sites using gadopentetate-RGD and gadopentetate-somatostatin conjugates. No gadopentetate peptide conjugate has progressed to clinical use, as most targeted MRI development has focused on nanoparticle platforms or alternative chelate chemistries with improved relaxivity and safety profiles.

Route of Administration

Intravenous

Regulatory Status

Research Phase

Interested in Gadopentetate Peptide Conjugates?

Find a verified provider experienced with Gadopentetate Peptide Conjugates protocols in your area. All providers are credentialed and use compliant sourcing.

Find a Gadopentetate Peptide Conjugates Provider

Related Peptides

Pentagastrin

FDA Approved

A synthetic pentapeptide containing the C-terminal tetrapeptide sequence of gastrin (Trp-Met-Asp-Phe-NH2) linked to beta-alanine. Pentagastrin stimulates gastric acid secretion by binding to cholecystokinin-2 (CCK2) receptors on parietal cells, and stimulates calcitonin release from thyroid C-cells. It has been used as a diagnostic agent for both gastric acid secretory capacity testing and provocative testing for medullary thyroid carcinoma (MTC).

DOTATATE (Ga-68)

FDA Approved

Gallium-68 DOTATATE is a radiolabeled somatostatin analog consisting of an octapeptide (Tyr3-octreotate) conjugated to the macrocyclic chelator DOTA, which binds the positron-emitting radioisotope gallium-68. It exhibits high affinity for somatostatin receptor subtype 2, which is overexpressed on neuroendocrine tumor cells, enabling PET imaging of these malignancies. The 68-minute half-life of gallium-68 and the rapid pharmacokinetics of the peptide provide excellent tumor-to-background ratios within 1 to 2 hours post-injection.

Bombesin Analog Tracers

In Clinical Trials

Bombesin analog tracers are synthetic peptides based on the 14-amino acid amphibian peptide bombesin or its mammalian counterpart gastrin-releasing peptide (GRP), radiolabeled for molecular imaging. These analogs bind to GRP receptors, which are overexpressed in prostate, breast, and small cell lung cancers, enabling tumor visualization via PET or SPECT imaging. Various radionuclides including gallium-68, fluorine-18, technetium-99m, and copper-64 have been conjugated to bombesin antagonist and agonist peptides.

RGD Peptide Tracers

In Clinical Trials

RGD peptide tracers are short synthetic peptides containing the arginine-glycine-aspartic acid (RGD) tripeptide sequence, which binds to integrin receptors, particularly alphavbeta3, conjugated to positron or gamma-emitting radioisotopes. Alphavbeta3 integrin is upregulated on angiogenic endothelium and many cancer cells, making RGD tracers useful for imaging tumor angiogenesis, metastatic disease, and potentially cardiovascular pathology. Cyclic RGD peptides and multimeric constructs have been developed to improve binding affinity and tumor retention.